BioPharma Dive June 14, 2024
The Japanese pharma paid $100 million to secure option rights to a third-generation TKI inhibitor, while a venture arm of the big investment bank closed its inaugural life sciences fund.
Today, a brief rundown of news from Takeda and the Food and Drug Administration, as well as updates from Insmed, J.P. Morgan and Bristol Myers Squibb that you may have missed from earlier this week.
Takeda Pharmaceutical has paid $100 million for an exclusive option to license a blood cancer medicine from China-based Ascentage Pharma. Known as olverembatinib, the medicine is already approved and marketed in China for certain adult patients with chronic myeloid leukemia. It blocks members of the “tyrosine kinase” enzyme family that are integral to the onset...
Today's Sponsors
Today's Sponsor